Quote:

---

What I am telling them is that it is a long-term hold with the chance to get to $20 in the next couple of years.

---

Let's reverse engineer a $20 share price. The analysis does not factor in COVID-19 or potential for future indications.

$20 a share x 700m shares = $14b market cap
$14b / 12PE = $1.17b earnings
With a 20% net* $1.17b x 5 = $5.85 revenue
$5.85b / $1542 dose price = 3,793.774 doses
3.793,774 / 52 weekly doses = 72,957 patients

72,597 patients worldwide* is high for combo therapy but should be achievable for monotherapy. In cancer I would expect an absolute minimum of 200,000 patients worldwide. Take into account another 49+ indications even though some will be short time treatment and it's enough to make your head reel.

*20% net ($308 dose) is what I think can be averaged worldwide with varying pricing models.